Maravai LifeSciences Holdings, Inc. announced that its preliminary unaudited 2024 revenue is expected to be near the mid-point of its previously announced guidance range of $255.0 million and $265.0 million. This provides an early indication of the company's full-year financial performance.
The company also stated its intention to announce its fourth quarter and full year 2024 financial and operating results on Tuesday, February 25, 2025. This preliminary update precedes the comprehensive audited financial report.
Maravai cautioned that these preliminary revenue results are subject to year-end closing adjustments and audit, and actual results may differ from the current expectations. Investors will await the full audited report for complete financial details.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.